RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition
Cancer Cell · 2026
DOI: 10.1016/j.ccell.2025.09.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2026. Verfasst von Eli L Diamond und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: MAP Kinase Kinase 1, MAP Kinase Kinase 2, Mutation, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Paris-Saclay University, Versailles SQY University, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, 92100 Boulogne, France.
- Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Sorbonne University, Assistance Publique-Hôpitaux de Paris, Pitié-Salpȇtrière Hospital, Internal Medicine Department 2, French Reference Centre for Histiocytosis, CIMI INSERM-UMRS 1135, 75013 Paris, France.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- National Institutes of Health National Cancer Institute
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- National Cancer Center
- American Society of Hematology
- National Institutes of Health
- West Family Foundation
Zitieren
APA
Diamond, E. L., Emile, J. F., Fujino, T., Haroche, J., Maron, M. I., Lewis, A. M., Rahman, J., Reiner, A. S., Bossert, D., Rosenblum, M., Yabe, M., Petrova-Drus, K., Francis, J. H., Rotemberg, V., Rampal, R. K., Yoo, S., Daniyan, A. F., Mahajan, S., Hatzoglou, V., …, & Durham, B. H. (2026). RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.09.014
Vancouver
Diamond EL, Emile JF, Fujino T, Haroche J, Maron MI, Lewis AM, et al. RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer Cell. 2026. doi:10.1016/j.ccell.2025.09.014
BibTeX
@article{Diamond2026,
author = {Diamond, Eli L and Emile, Jean-Francois and Fujino, Takeshi and Haroche, Julien and Maron, Maxim I and Lewis, Alexander M and Rahman, Jahan and Reiner, Anne S and Bossert, Dana and Rosenblum, Marc and Yabe, Mariko and Petrova-Drus, Kseniya and Francis, Jasmine H and Rotemberg, Veronica and Rampal, Raajit K and Yoo, Sarah and Daniyan, Anthony F and Mahajan, Sonia and Hatzoglou, Vaios and Young, Robert and Ulaner, Gary A and Rösler, Wiebke and Hershkovitz-Rokah, Oshrat and Shpilberg, Ofer and Mazor, Roei D and Chen, Luke Y C and Singer, Michael and Cuibus, M Adriana and Weis, Kenyon and Benbarche, Salima and Zhang, Pu and Fox, Nina and Castro, Cynthia and Tittley, Steven and Witkowski, Matthew and Cohen-Aubart, Fleur and Terriou, Louis and Hanoun, Maher and Schleinitz, Nicolas and Sosa, Gabriela and Hautala, Timo and De Lassus, Laure Farnault and Rosen, Neal and Abdel-Wahab, Omar and Durham, Benjamin H},
title = {RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition},
journal = {Cancer Cell},
year = {2026},
doi = {10.1016/j.ccell.2025.09.014}
}
EUVIMED